Jackson Creek Investment Advisors LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Jackson Creek Investment Advisors LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 53,108 shares of the company’s stock, valued at approximately $1,284,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. US Bancorp DE raised its stake in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after buying an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth about $48,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at $4,659,976.07. The trade was a 3.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,062,011 shares of company stock worth $36,892,724. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $36.01 on Friday. The firm’s 50-day simple moving average is $37.45 and its 200-day simple moving average is $27.31. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The firm has a market cap of $8.00 billion, a P/E ratio of 81.85 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Truist Financial lifted their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Piper Sandler raised their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, Leerink Partners lifted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $37.23.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.